29 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).
Salk Institute
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.
Salk Institute
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
Salk Institute
Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Salk Institute
Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
Salk Institute
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Salk Institute
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Salk Institute
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
Salk Institute
Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Salk Institute
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.
Salk Institute
Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Salk Institute
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.
Salk Institute
Synthesis, in vivo and in vitro biological activity of novel azaline B analogs.
Salk Institute
Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.
Salk Institute
Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.
Salk Institute
Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Salk Institute
Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).
Salk Institute
Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling.
Salk Institute
Design of potent dicyclic (1-5/4-10) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
Design of potent dicyclic (4-10/5-8) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Salk Institute
Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Salk Institute
Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N omega-cyanoguanidino moieties.
Salk Institute
Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6.
Salk Institute
